Author

C. Gekas

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:machine learning (classical)· 1 Approach:statistical model· 1 Research Focus:synaptic & neural circuits· 1

Frequent Co-Authors

A. Bigas· 1 shared A. Vo· 1 shared C. Jeffries· 1 shared C. Lu· 1 shared C. Ramathal· 1 shared D. Arambilet· 1 shared D. Verduzco· 1 shared E. Murphy· 1 shared

Activity by Year

2022-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Bigas

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

β-catenin activity induces an RNA biosynthesis program promoting therapy resistance in T Acute Lymphoblastic Leukemia

V. Garcia-Hernandez, D. Arambilet, Y. Guillen, T. Lobo, C. Gekas, N. Vega-Garcia, I. Sentis, J. L. Trincado, I. Marquez-Lopez, H. Heyn, M. Camos, L. Espinosa, A. Bigas

The paper identifies a β-catenin-regulated RNA biosynthesis program linked to therapy resistance in T-ALL and suggests combining chemotherapy with β-catenin inhibitors to improve treatment outcomes.

bioRxiv · Jul 7, 2022Cancer Biology

TCGADEPMAP -- Mapping Translational Dependencies and Synthetic Lethalities within The Cancer Genome Atlas

X. Shi, C. Gekas, D. Verduzco, S. Petiwala, C. Jeffries, C. Lu, E. Murphy, T. Anton, A. Vo, Z. Xiao, P. Narayanan, M. Barnes, S. Roy, C. Ramathal, M. J. Flister, Z. Dezso

TCGADEPMAP maps translational tumor dependencies and synthetic lethality using TCGA data, identifying novel targets like PAPSS1/2 with clinical implications.

bioRxiv · Mar 24, 2022 · PreprintCancer Biology